Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
norovirus bivalent vaccine (Vaxart, Inc.)
- Development stage
- Unknown
- Lead developer
- Vaxart
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
VXA-NVV-104 is an investigational, bivalent oral pill vaccine developed by Vaxart for the prevention of norovirus-associated acute gastroenteritis. The vaccine utilizes Vaxart's proprietary VAAST (Vector-Adjuvant-Antigen Standardized Technology) platform, which employs a non-replicating adenovirus type 5 (Ad5) vector to deliver genes encoding the VP1 capsid proteins of norovirus GI.1 and GII.4 genogroups. It also incorporates a double-stranded RNA (dsRNA) molecule that acts as a Toll-like receptor 3 (TLR3) agonist adjuvant to stimulate a mucosal immune response in the small intestine. By targeting the gut-associated lymphoid tissue (GALT) via an enteric-coated tablet, the vaccine aims to induce both systemic and mucosal immunity, potentially providing protection against norovirus infection and transmission. It is currently in Phase 2 clinical development.
- Other names
- Norovirus Oral Pill VaccineVaxart Norovirus VaccineNorovirus Bivalent (First-Generation)
02
Targets
TLR3 (Toll-like receptor 3)GII.4 VP1 (Norovirus GII.4 VP1)
Beyond the preview
Go deeper on norovirus bivalent vaccine (Vaxart, Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on norovirus bivalent vaccine (Vaxart, Inc.).